Impact of the timing of metformin administration on glycaemic and glucagon-like peptide-1 responses to intraduodenal glucose infusion in type 2 diabetes: a double-blind, randomised, placebo-controlled, crossover study.

What Was Tested

The paper reports a study of Glucagon, published as a randomized controlled trial.

Metformin lowers postprandial glycaemic excursions in individuals with type 2 diabetes by modulating gastrointestinal function, including the stimulation of glucagon-like peptide-1 (GLP-1).

The impact of varying the timing of metformin administration on postprandial glucose metabolism is poorly defined.

The researchers evaluated the effects of metformin, administered at different intervals before an intraduodenal glucose infusion, on the subsequent glycaemic, insulinaemic and GLP-1 responses in metformin-treated type 2 diabetes.

Why It Was Studied

Www.anzctr.org.au ACTRN12621000878875 FUNDING: The study was not funded by a specific research grant.

Who Took Part

The age groups tagged for this paper are adults, middle-aged adults and older adults, both men and women.

The treatments were blinded to both participants and investigators involved in the study procedures.

How the Study Was Run

The researchers set it up as a randomized, double-blind and crossover study.

Because people in this Glucagon study were split into groups at random, differences between the groups are less likely to reflect who happened to join each one.

Blinding on both sides kept the participants and researchers unaware of who received Glucagon.

In the crossover set-up each of the participants took both Glucagon and the comparison in turn, acting as their own control.

Plasma glucose, insulin and total GLP-1 levels were measured every 30 min between t = -60 min and t = 120 min.

What Was Measured

The subject headings attached to it are Metformin, Diabetes Mellitus, Type 2, Glucagon-Like Peptide 1, Blood Glucose, Hypoglycemic Agents, Glucose and Insulin.

The authors tagged it with the keywords Glucagon-like peptide-1, Postprandial glycaemia, Preload and Type 2 diabetes.

What This Means in Plain Language

The paper is a randomized, double-blind and crossover study of Glucagon.

Results are reported in around 5 sentences of the abstract; we leave them to the paper itself rather than summarise them.

The publication is from 2024 (Diabetologia), a journal based in Germany.

More context: the Glucagon compound page, all human trials.